INOmax
PreclinicalSmall molecule
INOmax is one of 46 small molecule programs targeting Pulmonary Hypertension. It is currently in Preclinical.
2
Indications
2
Total Trials
0
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
51 competitors in Pulmonary Hypertension
#DrugCompanyPhaseTrials
1Viagra
VViatris Specialty LLC
Approved
Letairis
GileadApproved
Remodulin
United TherapeuticsApproved
Cialis
Eli LillyApproved
Adempas
BayerApproved
Tracleer
Johnson & JohnsonApproved
Opsumit
Johnson & JohnsonApproved
Primacor
SanofiApproved
Levitra
BayerApproved
Ranexa
MMenarini International Operations Luxembourg SA
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for INOmax. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- MMallinckrodt